Monopar Therapeutics (MNPR) Payables (2016 - 2025)
Quarterly results put Payables at $2.7 million for Q4 2025, up 21.33% from a year ago — trailing twelve months through Dec 2025 was $2.7 million (up 21.33% YoY), and the annual figure for FY2025 was $2.7 million, up 21.33%.
Monopar Therapeutics has reported Payables over the past 10 years, most recently at $2.7 million for Q4 2025.
- Payables reached $2.7 million in Q4 2025 per MNPR's latest filing, up from $2.6 million in the prior quarter.
- Across five years, Payables topped out at $3.1 million in Q4 2022 and bottomed at $806272.0 in Q1 2021.
- Median Payables over the past 5 years was $1.7 million (2023), compared with a mean of $1.8 million.
- The largest annual shift saw Payables skyrocketed 168.85% in 2023 before it plummeted 56.45% in 2024.
- Over 5 years, Payables stood at $1.6 million in 2021, then surged by 97.96% to $3.1 million in 2022, then crashed by 43.83% to $1.8 million in 2023, then increased by 28.28% to $2.3 million in 2024, then rose by 21.33% to $2.7 million in 2025.
- Business Quant data shows Payables for MNPR at $2.7 million in Q4 2025, $2.6 million in Q3 2025, and $1.6 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 1.03 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - | 2.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.74 Mn |
| Sep 30, 2025 | 2.57 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 2.25 Mn |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 1.44 Mn |
| Dec 31, 2023 | 1.76 Mn |
| Sep 30, 2023 | 1.98 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 2.89 Mn |
| Dec 31, 2022 | 3.13 Mn |
| Sep 30, 2022 | 1.91 Mn |
| Jun 30, 2022 | 2.19 Mn |
| Mar 31, 2022 | 1.07 Mn |
| Dec 31, 2021 | 1.58 Mn |
| Sep 30, 2021 | 1.24 Mn |
| Jun 30, 2021 | 1.10 Mn |
| Mar 31, 2021 | 806,272.00 |
| Dec 31, 2020 | 1.18 Mn |
| Sep 30, 2020 | 542,068.00 |
| Jun 30, 2020 | 525,748.00 |
| Mar 31, 2020 | 443,520.00 |
| Dec 31, 2019 | 724,165.00 |
| Sep 30, 2019 | 483,666.00 |
| Jun 30, 2019 | 468,272.00 |
| Mar 31, 2019 | 579,986.00 |
| Dec 31, 2018 | 399,551.00 |
| Sep 30, 2018 | 311,893.00 |
| Jun 30, 2018 | 323,063.00 |
| Mar 31, 2018 | 290,597.00 |
| Dec 31, 2017 | 311,867.00 |
| Dec 31, 2016 | 64,510.00 |